STOCK TITAN

Harvard Bioscience Inc - $HBIO STOCK NEWS

Welcome to our dedicated page for Harvard Bioscience news (Ticker: $HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Bioscience stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Harvard Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Harvard Bioscience's position in the market.

Rhea-AI Summary

Harvard Bioscience, Inc. (Nasdaq: HBIO) announced its first quarter 2024 financial results, reporting revenues of $24.5 million, a gross margin of 60.3%, and adjusted EBITDA of $1.6 million. Despite challenges in certain markets, the company remains focused on efficiency and growth, with a cost reduction initiative in place. The net loss for the quarter was $(4.7) million, with a decrease in revenues compared to the prior year. The company expects flat revenues for 2024, with second-half growth and a gross margin of 60%. Harvard Bioscience will be hosting a conference call to discuss the results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
-
Rhea-AI Summary

Harvard Bioscience, Inc. (Nasdaq: HBIO) will release its first quarter 2024 financial results on May 7, 2024. The company will hold a conference call at 8:00 AM ET to discuss the results. Participants can register to join the call and ask questions. Financial information will be accessible on the Investor Relations section of Harvard Bioscience's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
-
Rhea-AI Summary
Harvard Bioscience, Inc. (HBIO) has announced a labor force reduction to enhance operational efficiency and support growth investments. The company anticipates $4 million in annual savings starting Q2 2024 with restructuring charges of $0.5 million. CEO Jim Green emphasizes the move's alignment with strategic priorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.42%
Tags
none
Rhea-AI Summary
Harvard Bioscience, Inc. (HBIO) announces CEO Jim Green and CFO Jennifer Cote will present at Sidoti Small Cap Conference and KeyBanc Life Sciences & MedTech Conference in March 2024. The presentations will be webcast live on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
conferences
-
Rhea-AI Summary
Harvard Bioscience, Inc. (HBIO) announced Q4 revenues of $28.2 million with a gross margin of 58.0% and operating income of $0.3 million. The company focused on debt reduction and net leverage improvement. Despite a slight revenue decline, the company saw gross margin expansion and introduced new products targeting high-growth markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.73%
Tags
-
Rhea-AI Summary
Harvard Bioscience, Inc. (HBIO) introduces new product innovations at the Society of Toxicology conference, showcasing solutions for CROs, pharma, and biotechs to enhance data analytics and therapy development. The latest offerings include the Ponemah Data Management Platform, SoHo Implantable Telemetry, VivaMARS Activity Monitoring System, and Mesh MEA Organoid Platform, aiming to improve efficiency, reduce cycle times, and advance preclinical testing. The company's focus on integrating new technologies like AI and machine learning signifies a step towards streamlining data analysis and reporting in toxicology and organoid testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
none
Rhea-AI Summary
Harvard Bioscience, Inc. (HBIO) will release its financial results for Q4 2023 on March 7, 2024. A conference call will be held at 8:00 a.m. Eastern Time for discussion. Participants can register to join the call and access the webcast for more details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
-
Rhea-AI Summary
Harvard Bioscience, Inc. (Nasdaq: HBIO) to Present at Benchmark Company 12th Annual Discovery One-on-One Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Harvard Bioscience, Inc. (Nasdaq: HBIO) announced that Chairman and CEO Jim Green, along with CFO Jennifer Cote, will present at the Southwest IDEAS Investor Conference on November 16, 2023. The presentation will be available for replay on the company's website. One-on-one meetings with investors will also be hosted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
conferences
Rhea-AI Summary
Harvard Bioscience, Inc. (HBIO) reported Q3 revenues of $25.4 million with a gross margin of 58.1%. GAAP operating loss was $0.9 million, adjusted operating income was $1.8 million. Debt was reduced by $8.3 million through Q3. Q3 revenues declined by 6% compared to the same period last year. Adjusted EBITDA for Q3 was $2.2 million, and cash provided by operations was $4.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
Harvard Bioscience Inc

Nasdaq:HBIO

HBIO Rankings

HBIO Stock Data

162.83M
35.10M
7.29%
78.38%
1.47%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
HOLLISTON

About HBIO

harvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.